JAK inhibition ameliorates bone destruction by simultaneously targeting mature osteoclasts and their precursors.

This is the first study to determine the pharmacological actions by which a JAK inhibitor blocks bone destruction under inflammatory conditions; this inhibition is beneficial because of its dual effects on both mature osteoclasts and immature osteoclast precursors.